Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

7.4%

2 terminated/withdrawn out of 27 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

11%

3 trials in Phase 3/4

Results Transparency

9%

2 of 22 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
12(50.0%)
Phase 1
8(33.3%)
Phase 3
3(12.5%)
N/A
1(4.2%)
24Total
Phase 2(12)
Phase 1(8)
Phase 3(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT04687059Phase 2Completed

An Exploratory Study of PQ Grass 27600 SU

Role: lead

NCT07412990Recruiting

GRASS (Grass MATA MPL Real-world Assessment Study)

Role: lead

NCT05476497Phase 1Active Not Recruiting

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

Role: lead

NCT05186025Active Not Recruiting

Tyrosine Allergoid Paediatric and Adult Study

Role: lead

NCT05540717Phase 3Completed

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Role: lead

NCT05455749Not ApplicableCompleted

Effect of holoBLG on Cat Allergic Patients

Role: lead

NCT00109759Phase 1Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Role: lead

NCT00133146Phase 2Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Role: lead

NCT00258635Phase 2Completed

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Role: lead

NCT00133159Phase 2Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Role: lead

NCT00118612Phase 2Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Role: lead

NCT04389034Completed

Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels

Role: lead

NCT02582073Phase 2Completed

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Role: lead

NCT00387478Phase 2Terminated

Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis

Role: lead

NCT03931993Phase 1Completed

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

Role: lead

NCT02557633Phase 1Completed

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

Role: lead

NCT00113750Phase 2Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Role: lead

NCT00116285Phase 1Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Role: lead

NCT00325338Phase 2Completed

Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis

Role: lead

NCT00107705Phase 1Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Role: lead